Boston Sci sees Q3 profit drop; Teleflex to sell aerospace businesses to AAR;

> Boston Scientific ($BSX) saw their third-quarter profit decline 25% with demand dipping for its defibrillators and pacemakers. Story

> Teleflex ($TFX), which makes specialty medical devices, among other things, has entered into a definitive agreement to sell its cargo systems and container aerospace businesses to a subsidiary of AAR ($AIR) for $280 million. Teleflex release

> Agendia has appointed David Macdonald as CEO following the resignation of Dr. Bernhard Sixt. Agendia release

> The FDA is advising against the use of jet injectors to administer influenza vaccines, according to Bioject Medical Technologies. The agency recommends that all vaccines be administered in accordance with their labeling. Bioject release

> Zimmer Holdings ($ZMH) is showcasing its PathFinder NXT system at the 2011 EuroSpine meeting. The system builds on the legacy of the original PathFinder minimally invasive pedicle screw system to provide an intuitive, flexible system for a range of minimally invasive spinal procedures. Zimmer release

> Teleflex ($TFX) has launched the ArrowADVANTAGE5 pressure-injectable peripherally inserted central catheter, which has what the company calls 5 unique advantages. Teleflex release

And Finally... An ex-Wall Street banker has emerged as a key figure in the scandal engulfing Olympus. Hajime 'Jim' Sagawa owned an obscure U.S. financial firm that was hired by the endoscope maker 5 years ago to provide what later turned out to be very expensive advice, documents show. News